| Literature DB >> 22046323 |
Bhavna Chawla1, Anupam Jhingran, Aswini Panigrahi, Kenneth D Stuart, Rentala Madhubala.
Abstract
Leishmania donovani is a protozoan parasite that causes visceral leishmaniasis (VL) and is responsible for significant mortality and morbidity. Increasing resistance towards antimonial drugs poses a great challenge in chemotherapy of VL. Paromomycin is an aminoglycosidic antibiotic and is one of the drugs currently being used in the chemotherapy of cutaneous and visceral leishmaniasis. To understand the mode of action of this antibiotic at the molecular level, we have investigated the global proteome differences between the wild type AG83 strain and a paromomycin resistant (PRr) strain of L. donovani. Stable isotope labeling of amino acids in cell culture (SILAC) followed by quantitative mass spectrometry of the wild type AG83 strain and the paromomycin resistant (PRr) strain identified a total of 226 proteins at ≥ 95% confidence. Data analysis revealed upregulation of 29 proteins and down-regulation of 21 proteins in the PRr strain. Comparative proteomic analysis of the wild type and the paromomycin resistant strains showed upregulation of the ribosomal proteins in the resistant strain indicating role in translation. Elevated levels of glycolytic enzymes and stress proteins were also observed in the PRr strain. Most importantly, we observed upregulation of proteins that may have a role in intracellular survival and vesicular trafficking in the PRr strain. Furthermore, ultra-structural analysis by electron microscopy demonstrated increased number of vesicular vacuoles in PRr strain when compared to the wild-type strain. Drug affinity pull-down assay followed by mass spectrometery identified proteins in L. donovani wild type strain that were specifically and covalently bound to paromomycin. These results provide the first comprehensive insight into the mode of action and underlying mechanism of resistance to paromomycin in Leishmania donovani.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22046323 PMCID: PMC3203147 DOI: 10.1371/journal.pone.0026660
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Experimental outline of the SILAC experiment.
Paromomycin resistant cells (PRr) and AG83 wild type (WT) were grown on isotopically heavy and light media respectively. The cells from both the strains were lysed and light and heavy cell lysates were combined. Protein samples were reduced, alkylated and digested with trypsin into peptide samples that were then analyzed by LC-MS/MS. Quantification of SILAC peptide pairs was performed with the SEQUEST algorithm against L. infantum protein database ver 3.0 (ftp://ftp.sanger.ac.uk/pub/pathogens/L_infantum/). The SEQUEST output files were analyzed and validated by PeptideProphet.
Figure 2Pie diagram showing distribution of Leishmania proteins identified by quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels between paromomycin resistant (PRr) and sensitive cells.
Proteins were grouped according to their cellular functions. The up- and down- regulated hits are combined in each group.
Proteins upregulated in the paromomycin resistant (PRr) strain.
| S. No. | Accession No. | Name of the Protein(Up-regulated) | PRr:WT ratio | P-value | Percent Coverage | Total Number of Peptides |
|
| ||||||
| 1 | LinJ15_V3.1530 | Ribosomal protein S6, putative | 1.57±0.4 | 4.21E-01 | 34.9 | 6 |
| 2 | LinJ28_V3.0570LinJ30_V3.3240 | Ribosomal protein s26, putative | 3.47±0.6 | 2.05E-02 | 15.2 | 2 |
| 3 | LinJ28_V3.1050LinJ30_V3.3650 | 40S ribosomal protein S14 | 1.65±1 | 5.39E-01 | 29.2 | 14 |
| 4 | LinJ32_V3.0930LinJ35_V3.0600 | 60S ribosomal protein L18a, putative | 1.56±0.3 | 4.07E-01 | 6.7 | 3 |
| 5 | LinJ36_V3.0210 | Elongation factor 2 | 1.5 | 58.8 | 5 | |
|
| ||||||
|
| ||||||
| 6 | LinJ14_V3.1240 | Enolase | 2.4 | 67.8 | 9 | |
| 7 | LinJ21_V3.0300LinJ21_V3.0310 | Hexokinase, putative | 1.5±1.1 | 6.52E-01 | 10.6 | 8 |
| 8 | LinJ24_V3.0870 | Triosephosphate isomerase | 1.51±0.5 | 5.06E-01 | 10.8 | 9 |
| 9 | LinJ30_V3.2990LinJ30_V3.3000 | Glyceraldehyde 3-phosphate dehydrogenase, glycosomal | 1.94±0.6 | 2.68E-01 | 30.2 | 138 |
| 10 | LinJ36_V3.6960 | 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | 1.57±0.6 | 4.85E-01 | 5.6 | 2 |
|
| ||||||
| 11 | LinJ16_V30560 | Orotidine-5-phosphate decarboxylase/orotate phosphoribosyltransferase, putative | 1.56±0.5 | 4.66E-01 | 12 | 21 |
| 12 | LinJ24_V3.0780 | Malic enzyme | 1.78±1.5 | 5.52E-01 | 4.6 | 3 |
| 13 | LinJ27_V3.0300 | Acyl carrier protein, putative | 1.78±0.2 | 2.67E-01 | 12 | 4 |
| 14 | LinJ30_V3.3560LinJ30_V3.3580 | S-adenosylmethionine synthetase | 1.63±0.07 | 3.38E-01 | 2.3 | 2 |
|
| ||||||
| 15 | LinJ26_V3.1220 | Heat shock protein 70-related protein | 2.11±0.2 | 1.50E-01 | 15.8 | 7 |
| 16 | LinJ28_V3.3060 | Heat-shock protein hsp70, putative | 2.5467 | 62.5 | 10 | |
| 17 | LinJ30_V3.2480 | Heat shock 70-related protein 1, mitochondrial precursor, putative | 2.01 | 49.7 | 3 | |
| 18 | LinJ32_V3.3470 | Chaperonin alpha subunit, putative | 5.75±0.4 | 6.65E-04 | 7.9 | 5 |
| 19 | LinJ36_V3.7240 | Chaperonin, putative | 2.26±0.2 | 1.16E-01 | 7.8 | 6 |
|
| ||||||
| 20 | LinJ35_V3.2240 | RNA-binding protein, putative | 1.5±0.7 | 5.71E-01 | 12.4 | 8 |
| 21 | LinJ36_V3.3960 | Basic transcription factor 3a, putative | 2.68±0.9 | 1.07E-01 | 35 | 17 |
|
| ||||||
| 22 | LinJ11_V3.0350 | 14-3-3 protein, putative | 1.64±0.6 | 4.41E-01 | 13.4 | 7 |
| 23 | LinJ12_V3.0730 | NADH:flavin oxidoreductase/NADH oxidase, putative | 2.89±2.7 | 3.13E-01 | 9 | 5 |
| 24 | LinJ19_V3.0150 | Aminopeptidase, putative | 1.73±0.2 | 2.93E-01 | 11.1 | 6 |
| 25 | LinJ20_V3.0820 | Vesicle-fusing ATPase, putative | 2.8±0.4 | 5.21E-02 | 6.1 | 3 |
| 26 | LinJ24_V3.1560LinJ24_V3.1570 | IgE-dependent histamine-releasing factor, putative | 1.75±0.2 | 2.88E-01 | 5.3 | 2 |
| 27 | LinJ28_V3.2610 | Vacuolar ATP synthase subunit B, putative | 1.64±1.2 | 5.75E-01 | 4.8 | 2 |
| 28 | LinJ29_V3.0790 | Lipophosphoglycan biosynthetic protein, putative | 2.01±0.2 | 1.77E-01 | 5.6 | 3 |
| 29 | LinJ36_V3.3360 | 14-3-3 protein-like protein | 1.56±0.5 | 4.59E-01 | 22.9 | 10 |
List of proteins with increased expression levels in the PR resistant strain.
Fold change of protein level measured by SILAC with standard deviation is given as PRr:WT ratio.
p-value determined here were analyzed and validated by PeptideProphet.
Proteins downregulated in the paromomycin resistant (PRr) strain.
| S. No. | Accession No. | Name of the Protein(Down-regulated) | PRr:WT ratio | P-value | Percent coverage | Total Number of Peptides |
|
| ||||||
| 1 | LinJ11_V3.1160 | Eukaryotic release factor 3, putative | 0.17 | 1.45E-03 | 5.3 | 3 |
| 2 | LinJ18_V3.0630LinJ36_V3.3950 | 60S ribosomal protein L10a, putative | 0.24±0.2 | 1.99E-01 | 22 | 5 |
| 3 | LinJ22_V3.1370LinJ22_V3.1410 | 40S ribosomal protein L14, putative | 0.23±0.1 | 8.20E-03 | 5.2 | 4 |
| 4 | LinJ30_V3.0470 | Aspartyl-tRNA synthetase, putative | 0.09±0.01 | 8.88E-06 | 3.6 | 3 |
| 5 | LinJ35_V3.2040 | 60S ribosomal protein L32 | 0.27±0.2 | 1.88E-01 | 31.6 | 5 |
| Cell cytoskeleton | ||||||
| 6 | LinJ14_V3.1190 | Kinesin K39, putative | 0.3±0.04 | 2.40E-02 | 7.3 | 2 |
|
| ||||||
|
| ||||||
| 7 | LinJ20_V3.0110LinJ20_V3.0120 | Phosphoglycerate kinase C, glycosomal | 0.1±0.1 | 6.67E-02 | 19.1 | 14 |
|
| ||||||
| 8 | LinJ35_V3.0850 | NADH-dependent fumarate reductase-like protein | 0.47±0.07 | 1.62E-01 | 2.3 | 3 |
| 9 | LinJ35_V3.1190 | NADH-dependent fumarate reductase, putative | 0.24±0.02 | 5.57E-03 | 8.5 | 6 |
|
| ||||||
| 10 | LinJ05_V3.0500LinJ05_V3.0510 | ATPase alpha subunit | 0.45±0.27 | 3.12E-01 | 18.8 | 16 |
| 11 | LinJ12_V3.0620 | Cytochrome c oxidase subunit iv | 0.25±0.28 | 2.61E-01 | 7.4 | 2 |
|
| ||||||
| 12 | LinJ31_V3.2320 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative | 0.39±0.03 | 6.69E-02 | 8.8 | 2 |
| 13 | LinJ35_V3.3390 | 6-phosphogluconate dehydrogenase, decarboxylating putative | 0.36±0.03 | 4.79E-02 | 8.6 | 3 |
|
| ||||||
| 14 | LinJ21_V3.1330 | t-complex protein 1, delta subunit, putative | 0.47±0.03 | 1.40E-01 | 12 | 4 |
| 15 | LinJ35_V3.3900 | t-complex protein 1, eta subunit, putative | 0.42±0.1 | 1.09E-01 | 15.6 | 6 |
|
| ||||||
| 16 | LinJ15_V3.1500 | Proliferative cell nuclear antigen (PCNA), putative | 0.27±0.1 | 2.87E-02 | 11.6 | 3 |
| 17 | LinJ19_V3.0090 | Fibrillarin, putative | 0.45±0.1 | 1.69E-01 | 12.2 | 2 |
| 18 | LinJ32_V3.0410 | ATP-dependent RNA helicase, putative | 0.27±0.2 | 1.58E-01 | 11.9 | 6 |
|
| ||||||
| 19 | LinJ35_V3.0070 | Prohibitin, putative | 0.4±0.03 | 7.79E-02 | 7.9 | 2 |
|
| ||||||
| 20 | LinJ10_V3.0910 | Hypothetical protein, conserved | 0.47±0.1 | 1.48E-01 | 12.8 | 2 |
| 21 | LinJ35_V3.0140 | Hypothetical protein, conserved | 0.22±0.2 | 1.61E-01 | 21.8 | 3 |
List of proteins with decreased expression levels in the PR resistant strain.
Fold change of protein level measured by SILAC with standard deviation is given as PRr:WT ratio.
p-value reported here were analyzed and validated by PeptideProphet.
Figure 3Bar diagram showing the proteins that were up/downregulated in PR resistant strain.
The proteins have been grouped according to cellular functions based upon distinct peptides quantitated at ≥95% confidence and having ≥2 peptides.
Figure 4Transmission Electron Microscopic (TEM) images of the A. Wild Type (WT) promastigotes and B. Paromomycin resistant promastigotes.
WT promastigotes were harvested and fixed as mentioned in Materials and methods and subjected to TEM analysis. PRr strain displayed numerous vacuoles compared to the wild type strain. Images are representative of 2 independent experiments. FP: Flagellar Pocket; V: Vacuole; N: Nucleus; K: Kinetoplast.
Figure 5Overview of the affinity pull-down assay using PR-linked resin.
Paromomycin was bound to AminoLink Plus coupling resin. The PR-linked resin (experimental) and unlinked resin (used as negative control) were incubated with AG83 whole cell lysate. The beads were then washed and the resin was loaded onto 10% SDS-PAGE gel. The gel was stained with sypro ruby and the fragments were excised and digested with trypsin. The protein samples were analyzed by LC-MS/MS and the results compared to determine the proteins that interacted with PR selectively.
Drug affinity pull-down assays with in situ digestion and LC-MS/MS analysis identified proteins from wild type L. donovani promastigotes that bind to paromomycin.
| S. No. | Accession No. | Name of Protein | Number of Peptides | Probability | Percent coverage |
| 1. | LinJ16_V31510, LinJ16_V31520 | Paraflagellar rod protein 2C | 2 | 1 | 4.3 |
| 2. | LinJ18_V3.1490, LinJ18_V3.1500, LinJ18_V3.1510 | P-type H+-ATPase, putative | 3 | 0.99 | 5.8 |
| 3. | LinJ29_V3.1880,LinJ29_V3.1890 | Paraflagellar rod protein 1D | 5 | 1 | 9.3 |
| 4. | LinJ31_V3.2680 | RNA Polymerase II largest subunit | 1 | 0.99 | 1.1 |
| 5. | LinJ35_V3.0070 | Prohibitin | 1 | 0.95 | 4.8 |
The protein coverage is based on the non-redundant peptides identified by PeptideProphet.
The results are representative of two independent experiments.
Modulation in expression of proteins in paromomycin -susceptible (AG83 WT) and -resistant (PRr) Leishmania donovani.
| Cellular Function | Proteins modulated in the Paromomycin resistant strain |
| Intracellular Survival, Processing and Virulence | 14-3-3 protein, LPG biosynthetic protein and IgE dependent histamine release factor were found to be upregulated. Prohibitin was found to be downregulated. |
| Vesicle trafficking | Proteins involved in vesicle trafficking, fusion and endocytosis like vesicle fusing ATPase and vacuolar ATP synthase were found to be upregulated. |
| Translation | Ribosomal proteins were found to be upregulated in the PR resistant strain. This may be because PR is known to inhibit translation in |
| Chaperones/stress proteins | Heat shock proteins and chaperonins were found to be upregulated. HSPs protect cell from toxic external stimuli and have been implicated in drug resistance. |
| Metabolism | Proteins involved in glycolysis were seen to be upregulated |
Figure 6Proposed model for mechanism of paromomycin resistance in L. donovani.
(I) The drug paromomycin (red circles) interacts with paraflagellar rod proteins (blue circles) and prefoldin (yellow circles) and is then taken up by the Leishmania promastigotes by endocytosis. PR is then sequestered in to the vacuoles. The pump, vacuolar ATPase is found to be upregulated and the number of vacuoles is increased in the resistant parasites. (II) The chaperone proteins are found to be upregulated in the resistant cells as a result of the stress caused by paromomycin and are also involved in increased protein turnover. (III) A number of ribosomal protein subunits were found to be regulated, increasing the total protein synthesis. (IV) The glycolytic pathway was found to be upregulated. Proteins marked in red represent the upregulated proteins and the ones marked in green represent the down- regulated proteins in the case of paromomycin resistant strain. Enzymes indicated: (1) Hexokinase, (2) Phosphoglucose isomerase, (3) Phosphofructokinase, (4) Aldolase (5) Triose phosphate isomerase, (6) Glyceraldehyde 3-phosphate dehydrogenase, (7) Phosphoglycerate kinase (8) 2,3-bisphosphoglycerate independent phosphoglycerate mutase, (9) Enolase, (10) Pyruvate kinase, (11) Malic enzyme (12) glucose 6-phosphate dehydrogenase.